A study has found that the metabolic profiles of MGUS and myeloma patients are significantly different to those of healthy controls. Published in Blood Cancer Journal, the results suggested that the biggest metabolic changes within the bone marrow and plasma occurred during the development of MGUS rather than the later progression to myeloma. The most significant changes observed were decreases in the essential amino acids isoleucine and threonine in MGUS and myeloma patients compared to controls, suggesting increased anabolism of the cells occupying the bone marrow. Metabolic profiling may therefore provide a useful way of identifying MGUS patients and those at risk of progressing to myeloma and enable new treatment strategies to be developed by interfering with specific metabolic changes.

Read full article